| 戴秀梅,张有为,李劲松,陶云霞,冯 玉.减量依托泊苷联合顺铂治疗高龄小细胞肺癌的临床观察[J].现代生物医学进展英文版,2017,17(36):7057-7060. |
| 减量依托泊苷联合顺铂治疗高龄小细胞肺癌的临床观察 |
| Clinical Observation of Attenuated-dose Etoposide Plus Cisplatin(EP)Regimen on Elderly Patients with Small Cell Lung Cancer |
| Received:August 30, 2017 Revised:September 21, 2017 |
| DOI：10.13241/j.cnki.pmb.2017.36.013 |
| 中文关键词: 小细胞肺癌 高龄 减量化疗 |
| 英文关键词: Small-cell lung cancer Elderly Attenuated-dose chemotherapy |
| 基金项目:国家自然科学基金项目(81472615) |
|
| Hits: 24 |
| Download times: 20 |
| 中文摘要: |
| 摘要 目的：观察减量依托泊苷联合顺铂(EP)方案治疗高龄(≥70岁)小细胞肺癌(small-cell lung cancer，SCLC)的临床疗效和安全性。方法：收集2010年1月至2014年12月江苏省徐州市中心医院肿瘤内科初治的高龄SCLC患者30例，采用减量的EP方案化疗，观察其客观缓解率(objective response rate，ORR)、毒副反应的发生情况、无进展生存期(progression-free survival，PFS)、总生存期(overall survival，OS)及1年、2年、3年生存率。结果：高龄组一线减量EP方案化疗ORR为66.7%。局限期与广泛期中位PFS分别为10.0个月和9.0个月，差异无统计学意义(P＞0.05)。局限期与广泛期中位OS分别为19.0个月和17.0个月，差异无统计学意义(P＞0.05)。局限期与广泛期1年生存率分别为71.4%和68.8%，2年生存率分别为50.0%和25.0%，差异无统计学意义(P＞0.05)。局限期与广泛期3年生存率分别为35.7%和0%，差异有统计学意义(P＜0.05)。高龄组一线减量EP方案化疗III～IV级血液学毒性、恶心呕吐及乏力的发生率均≤20%。结论：减量EP方案治疗高龄小细胞肺癌疗效确切，毒副反应可耐受。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the efficacy and safety of attenuated-dose etoposide plus cisplatin(EP) regimen on the elderly patients(≥70 years) with small cell lung cancer(SCLC). Methods: Thirty cases of elderly patients with SCLC in the Department of Oncology of Xuzhou Central Hospital from January 2010 to December 2014 were enrolled and treated by attenuated-dose regimen of EP. The efficacy, incidence of adverse effects and survival state of patients were observed. Results: The objective response rate (ORR) of first-line attenuated-dose EP regimen-treated elderly patients with SCLC was 66.7%. The median progression-free survival(mPFS) was 10.0 months for the limited disease(LD)group and 9.0 months for the extensive disease(ED) group. The median overall survival(mOS) was 19.0 months for the LD group and 17.0 months for the ED group. There was no significant difference in the PFS or OS between the two groups(P＞0.05). The one-year survival rates were 71.4% and 68.8% respectively, the two-year survival rates were 50.0% and 25.0% respectively. There was no significant difference in the one-year survival rate or two-year survival rate between the LD group and the ED group (P＞0.05). The three-year survival rates were 35.7% and 0% respectively. There were significant differences in three-year survival rate between the LD group and the ED group (P＜0.05). The incidence of grade-Ⅲ～Ⅳ hematologic toxicities, nausea and vomiting, fatigue were ≤20% in the elderly patients with SCLC. Conclusion: Attenuated-dose regimen of EP is an effective chemotherapy in the initial treatment of elderly patients with SCLC and the adverse effects were tolerable. |
|
View Full Text
View/Add Comment Download reader |
| Close |
